Please note: In order to keep Hive up to date and provide users with the best features, we are no longer able to fully support Internet Explorer. The site is still available to you, however some sections of the site may appear broken. We would encourage you to move to a more modern browser like Firefox, Edge or Chrome in order to experience the site fully.

Supporting your high street Find out how »
Implementing a National Cancer Clinical Trials System for the 21st Century : Second Workshop Summary, Paperback / softback Book

Implementing a National Cancer Clinical Trials System for the 21st Century : Second Workshop Summary Paperback / softback

Edited by Margie Patlak, Sharyl J. Nass

Paperback / softback

Available to Order - This title is available to order, with delivery expected within 2 weeks

Description

The National Clinical Trials Network (NCTN) supported by the National Cancer Institute (NCI) has played an integral role in cancer research and in establishing the standard of care for cancer patients for more than 50 years.

Formerly known as the NCI Clinical Trials Cooperative Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally. Recognizing the recent transformative advances in cancer research that necessitate modernization in how cancer clinical trials are run, as well as inefficiencies and other challenges impeding the national cancer clinical trials program, the NCI asked the IOM to develop a set of recommendations to improve the federally funded cancer clinical trials system.

These recommendations were published in the 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. In early 2011, the NCPF and the American Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the changes they planned to implement in response to the IOM goals and recommendations.

Two years later, on February 11-12, 2013, in Washington, DC, the NCPF and ASCO reconvened stakeholders to report on the changes they have made thus far to address the IOM recommendations.

At this workshop, representatives from the NCI, the NCTN, comprehensive cancer centers, patient advocacy groups, the Food and Drug Administration (FDA), industry, and other stakeholders highlighted the progress that has been made in achieving the goals for a reinvigorated national cancer clinical trials system.

Implementing a National Cancer Clinical Trials System for the 21st Century is a summary of that workshop. Table of ContentsFront MatterImplementing a National Cancer Clinical Trials System for the 21stCenturyReferencesAcronymsAppendix A: Workshop Statement of Task and AgendaAppendix B: Executive Summary of *A National Cancer Clinical TrialsSystem for the 21st Century*

Information

Other Formats

Save 0%

£32.00

£31.85

Available to Order - This title is available to order, with delivery expected within 2 weeks
Add to Basket
Sign in to add to wishlist
 
Free Home Delivery

on all orders

 
Pick up orders

from local bookshops

Information